New Delhi, June 24
Low dose of emicizumab could be as effective as standard dose against Haemophilia A, according to a study led by the Indian Council of Medical Research (ICMR).
Emicizumab is a bispecific monoclonal antibody used to treat hemophilia A -- a genetic bleeding disorder.
The drug works by mimicking the function of the missing or deficient clotting factor VIII (FVIII), enabling blood clotting to occur and preventing or reducing bleeding episodes.
As per the official government data, there are 27,000 haemophilia patients registered and 1, 40,000 patients expected to be affected in India.
Low-dose emicizumab can also be potentially a cost-effective treatment option in persons with hemophilia A, especially in developing countries, the study revealed.
A standard dose of emicizumab is priced approximately at $15,000.